Projects per year
Cancer Biology | Tumor Progression | Metastasis | Intravasation
My research focuses predominantly on the molecular mechanisms of intravasation, the rate-limiting step of metastasis, and resistance/susceptibility of lymphovascular emboli to therapeutics.
Metastasis poses the single most difficult clinical challenge in the attempt to manage and treat cancer. In this effort, I have established patient-derived xenografts, signifcantly the first (and only) human transplantable inflammatory breast cancer xenograft, called MARY-X. Inflammatory breast cancer (IBC) is one of the most aggressive types of breast cancer; nearly 100% of all women with IBC have lymph node involvement and 25% have distant metastases upon diagnosis. The signature phenotype of IBC is florid lymphovascular invasion of cancer emboli. Whereas most human xenografts grow as a subcutaneous confluent cellular mass, MARY-X grows exclusively in the murine lymphatic and blood vessels, recapitulating the phenotype displayed in human IBC and in essence providing both a preclinical IBC model and a relevant model of metastasis. MARY-X, in vitro, is a primary cellular derivative from tumor explants. These tumor cells spontaneously form tight, compact aggregates of cells termed “MARY-X spheroids”. Comparable to human IBC emboli, a persistent, over-expression of an intact E-cadherin/α, β-catenin axis mediates the compaction of both in vitro and in vivo MARY-X spheroids and tumor emboli, respectively. The in vitro MARY-X spheroid has comparative 3-dimensional (3-D) architectural/pathophysiological features to the lymphovascular embolus. Therefore MARY-X provides a relevant 3D in vitro analysis platform for drug design and development of IBC and metastatic disease i.e. the lymphovascular embolus.
American Association for Cancer Research
Biochemistry, doctorate, University of Houston
Bachelor of Science, Bachelor
- 1 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
- 1 Finished
Correction to: Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research (Breast Cancer Research and Treatment, (2022), 192, 2, (235-243), 10.1007/s10549-021-06434-x)Susan G. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation, Apr 2022, In: Breast Cancer Research and Treatment. 192, 2, p. 245-247 3 p.
Research output: Contribution to journal › Comment/debate › peer-reviewOpen Access
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and researchSusan G. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation, Apr 2022, In: Breast Cancer Research and Treatment. 192, 2, p. 235-243 9 p.
Research output: Contribution to journal › Review article › peer-reviewOpen Access
Chiral resolution of a caged xanthone and evaluation across a broad spectrum of breast cancer subtypesChantarasriwong, O., Dorwart, T. J., Morales, T. H., Maggio, S. F., Settle, A. L., Milcarek, A. T., Alpaugh, M. L., Theodoraki, M. A. & Theodorakis, E. A., Dec 2019, In: Bioorganic Chemistry. 93, 103303.
Research output: Contribution to journal › Article › peer-review
& 13 others, Nov 11 2019, In: Cancer Cell. 36, 5, p. 559-573.e7
Research output: Contribution to journal › Article › peer-reviewOpen Access
Alpaugh, M. L., Bowden, M., Sicinska, E., Zhou, C. W., Karan, C., Realubit, R. B., Mundi, P. S., Grunn, A., Jäger, D., Chabot, J. A., Fojo, A. T., Oberstein, P. E., Hibshoosh, H., Milsom, J. W., Kulke, M. H., Loda, M., Chiosis, G., Reidy-Lagunes, D. L., & 1 others, Oct 1 2019, In: Nature Genetics. 51, 10, p. 1427-1428 2 p.
Research output: Contribution to journal › Letter › peer-review